A phase II trial of LMI-1195 for use in cardiac PET to assess myocardial presynaptic sympathetic nerve function
Phase of Trial: Phase II
Latest Information Update: 15 Mar 2018
Price : $35 *
At a glance
- Drugs LMI 1195 (Primary)
- Indications Heart failure; Ischaemic heart disorders
- Focus Diagnostic use
- 15 Mar 2018 New trial record
- 12 Mar 2018 Data from this trial will be presented at the American College of Cardiology's 67th Annual Scientific Session (ACC.18), according to a Lantheus Medical Imaging media release.
- 12 Mar 2018 Results presented in a Lantheus Medical Imaging media release.